MONTREAL, Nov. 12, 2019 /PRNewswire/ - Pharmascience Inc. is proud to announce that the US Food and Drug Administration (FDA) communicated on October 31, 2019, that the abbreviated new drug ...
PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI ® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in ...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced FDA approval of Invega Hafyera, a twice-yearly injectable antipsychotic for adults with schizophrenia. The approval of this 6-month ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the antipsychotic Paliperidone Janssen-Cilag International (Janssen-Cilag ...
The US Food and Drug Administration (FDA) has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera, Janssen Pharmaceuticals) for the ...
PP6M is a long-acting injectable antipsychotic designed to reduce the number of injections patients with schizophrenia receive. A supplemental New Drug Application (sNDA) for paliperidone palmitate ...
PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback